Stay updated on FIREFISH: Risdiplam in Type1 SMA Infants Clinical Trial
Sign up to get notified when there's something new on the FIREFISH: Risdiplam in Type1 SMA Infants Clinical Trial page.

Latest updates to the FIREFISH: Risdiplam in Type1 SMA Infants Clinical Trial page
- Check3 days agoChange DetectedThe site footer revision identifier changed from v3.7.0 to v3.7.1. The page continues to display a 403 error.SummaryDifference0.2%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe study detail page now shows a 403 Forbidden message, replacing the expected content and preventing users from accessing FIREFISH trial information.SummaryDifference20%

- Check24 days agoChange DetectedThe page revision was updated from v3.6.6 to v3.7.0, signaling a new version of the page. This change reflects an update to the page's metadata rather than the study content.SummaryDifference0.0%

- Check39 days agoChange DetectedThe page revision label was updated from v3.6.5 to v3.6.6 to reflect a new deployment of the FIREFISH study page.SummaryDifference0.0%

- Check46 days agoChange DetectedA 2016 NIH grant/contract reference was added to the study record, linking a U.S. NIH funding source to BP39056 (EudraCT 2016-000778-40) and providing funding context for the FIREFISH study.SummaryDifference0.0%

- Check60 days agoChange DetectedPublication citation for the FIREFISH study was updated from online-ahead-of-print to the final published Lancet Child Adolesc Health article (Sept 2026) with full authorship and DOI. This aligns the study record with the finalized publication details.SummaryDifference0.1%

Stay in the know with updates to FIREFISH: Risdiplam in Type1 SMA Infants Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FIREFISH: Risdiplam in Type1 SMA Infants Clinical Trial page.